P-gp plays a role in the cellular traffi cking of nanoscale drug carriers. In prior work, [ 8 ] we developed a gold nanoparticle delivery platform that preferentially targeted tumor stromal cells through surface presentation of macrolide small molecules, polarizing tumor associated macrophages towards an anti-tumor phenotype. Here, we use these novel nanoscale constructs to investigate the effects P-gp substrate presentation on the cellular traffi cking of PEGylated gold-nanorods.
P-gp plays a role in the cellular traffi cking of nanoscale drug carriers. In prior work, [ 8 ] we developed a gold nanoparticle delivery platform that preferentially targeted tumor stromal cells through surface presentation of macrolide small molecules, polarizing tumor associated macrophages towards an anti-tumor phenotype. Here, we use these novel nanoscale constructs to investigate the effects P-gp substrate presentation on the cellular traffi cking of PEGylated gold-nanorods.
To investigate P-gp ligand-dependent cellular traffi cking of nanoparticles, a series of colloidal gold nanorods were synthesized and conjugated with substrates of P-gp that exhibit varying degrees of susceptibility to P-gp-mediated effl ux, as reported previously.
[ 9 ] Figure 1 a illustrates the composition of these model nanoscale drug carriers, each comprised of 50 ± 8 × 13 ± 2 nm gold nanorods (Figure 1 b) surface functionalized with mixed (9:1) self-assembled monolayers of thiolated poly(ethylene glycol) (PEG) and one of the three thiol PEGylated macrolide antibiotics: azithromycin (Zithromax®), clarithromycin (Biaxin®), or tricyclic ketolide (TE-802). These gold nanorod (AuNR) conjugates are abbreviated hereafter as Azith-AuNRs, Clarith-AuNRs, and TriKeto-AuNRs, respectively. The macrolide ligands were synthesized by ' N -alkynylation of the corresponding desmethyl desosamine analogs, followed by Cu-catalyzed Huisgen cycloaddition (click) using an azide-modifi ed PEG-thiol (Supporting Data, Schemes S1-4). The gold nanorods were synthesized [ 8, 10 ] and conjugated [ 11 ] as described previously (see Supporting Information for detailed methods). Photon correlation spectroscopy, laser Doppler electrophoresis measurements, and surface plasmon extinction spectra from the purifi ed nanoparticle conjugates indicate stable surface ligation that was maintained in 10% serum-containing cell growth media over the time course of the experiments (Supporting Data, Figures S1,2) .
Cellular uptake of the nanoparticle conjugates was assessed using a lung macrophage cell line previously shown to exhibit P-gp-dependent accumulation of macrolide compounds, [ 9b ] where recognition has been shown to modulate pharmacokinetic and pharmacodynamic profi les of these drugs. [ 12 ] Consistent with known tissue disposition profi les of these ligands in lung macrophage cells, [ 13 ] macrolide-AuNRs exhibited dose-dependent accumulation in RAW264.7 cells that was signifi cantly greater than PEGylated control nanoparticles
Drug Carriers
Resistance to chemotherapy contributes to treatment failure in over 90% of patients with metastatic cancer. [ 1 ] Although, many tumors initially respond well to chemotherapies, selective pressure can lead to the proliferation and dissemination of cell subpopulations exhibiting either de novo or adaptive drug resistance, often accompanied by cross-resistance to a range of structurally diverse small molecule drugs. MDR1 P-glycoprotein (P-gp) is considered to be the most prevalent and single most important cause of multidrug-resistance (MDR) in humans, [ 2 ] where the protein facilitates recognition, intracellular traffi cking, sequestration, [ 3 ] and/or cellular effl ux of up to 50% of all cytotoxic chemotherapeutics (e.g. doxorubicin, paclitaxel, vinblastine, etoposide), as well as antibiotics (e.g. erythromycin, azithromycin, ketolides), and other therapeutic small molecules.
Gold nanoparticles are promising candidates for targeted anti-cancer drug delivery and laser photothermal therapy. [ 4 ] Phase I clinical trials have been successfully completed for the former [ 5 ] and human pilot studies [ 6 ] are currently in progress for the latter, both for the treatment of solid tumors in the US. Likewise, gold nanoparticle-based biodiagnostic platforms are rapidly accelerating towards the clinic.
(t = 24 h, Figure 1 c), where trends in nanoparticle accumulation qualitatively agree with the reported effi cacies of these drugs in treating drug-resistant infections.
[ 9c ] Confocal microscopy of fl uorescently-labeled nanoparticles ( Figure 1 d) further found that uptake and intracellular colocalization of the nanoparticles occurred in a manner consistent with that previously reported for both macrolide [ 14 ] and P-gp [ 9a ] accumulation in phagocytic cells.
Ligand-dependent cellular accumulation of the macrolide-AuNRs was next assessed following concurrent incubation with the P-gp competitive inhibitors, cyclosporine and verapamil, using both P-gp-expressing and P-gp-null cell lines. No signifi cant changes in the cellular accumulation of control PEG-AuNRs were observed following treatment with either inhibitor in P-gp(-) COLO 205 cells [ 15 ] or in P-gp(+) J774.2 cells [ 9a ] ( Figure 2 a,b). In contrast, while P-gp-dependent cell accumulation of macrolide-AuNRs was not observed in P-gp-null COLO 205 cells, accumulation of Azith-and Clarith-AuNR was signifi cantly increased in P-gp(+) J774.2 cells following competitive inhibition, with no signifi cant changes in TriKetoAuNR accumulation. These fi ndings agree well with previous reports indicating i) macrolide-competitive P-gp binding by verapamil and cyclosporine, [ 16 ] ii) diminished recognition of TriKeto (TE-802) by P-gp, [ 9f ] iii) enhanced in vivo effi cacy of third-generation tricyclic ketolides, [ 9d , 9e ] and iv) P-gp-dependent accumulation/ cytotoxicity of free macrolide ligands (Supporting Data, Figure S3 ). These data suggest that P-gp-dependent traffi cking can signifi cantly affect the cellular accumulation of nanoscale drug carriers to which P-gp substrates are appended (e.g. cytotoxic chemotherapeutics, [ 1, 17 ] macrolide/ketolide antibiotics, [ 9a , 18 ] fl uorescent imaging agents, [ 18 ] etc.). Concurrent optical dark-fi eld scattering microscopy [ 19 ] (DFSM) of nanoparticle-and P-gp inhibitor-treated cells ( Figure S4 ).
Finally, P-gp-dependent effl ux of macrolide-AuNRs was quantitatively evaluated by DFSM live-cell imaging, as described previously. [ 19b , 20 ] Following incubation of P-gp(+) J774.2 cells with 0.01 nM Azith-AuNRs, cell solutions were replaced with verapamil-spiked growth media and nanoparticle effl ux kinetics (i.e. cell associated surface plasmon scattering [ 11b , 21 ] ) were monitored over time ( Figure 3 a) . In the absence of competitive P-gp inhibition, nanoparticle effl ux rates were notably slower than that previously reported for free azithromycin in J774.2 cells (k = 0.14 ± 0.03 h −1 v. ca. 0.7 h −1 , [ 9a ] respectively), in agreement with the notion that nanoparticle conjugation can mitigate multidrug resistance through decreased P-gp-dependent cell effl ux (Figure 3 b) . With competitive P-gp inhibition, the rate of nanoparticle effl ux was further decreased (k = 0.036 ± 0.01 h −1 ), suggesting a role for P-gp in ligand-dependent cellular traffi cking of multivalent nanoparticle-drug conjugates.
P-glycoprotein is expressed on the plasma membrane, [ 9b-f ] as well as in lysosomes, and in both early and recycling endosomes. [ 22 ] where it is known to mediate the cellular traffi cking of small molecule drugs (host detoxifi cation) through both transmembrane effl ux [ 9f , 23 ] and trapping in acidic vesicles, [ 3, 24 ] respectively. Moreover, P-gp is also known to modulate cholesterol transport form the plasma membrane to the endoplasmic reticulum via endosomal recycling, [ 25 ] as well as plasma membrane reorganization through fl ippase-mediated depletion of cholesterol-interacting sphingomyelin, [ 25a , 26 ] processes which could both signifi cantly alter the intracellular traffi cking of non-polar P-gp substrate compounds and their respective nanoparticle-drug conjugates. Confocal microscopy experiments (Figure 1 d) found that both macrolide-and PEG-AuNRs co-localize in pericellular vesicles with fl uorescently-labeled dextran, consistent with liganddependent (Figure 1 c) endocytotic uptake of the nanoparticles and also in agreement with subcellular co-localization patterns previously reported for both P-gp [ 9a ] and macrolides [ 14 ] in J774 cells. These fi ndings suggest a partial role for P-gp-mediated lysosomal sequestration [ 3, 24 ] or cholesterol traffi cking [ 25, 26 ] in the cellular accumulation of macrolideAuNRs. P-gp substrate-competitive nanoparticle accumulation data (Figure 2 a-c) showed that inhibition of P-gp increased the net accumulation of P-gp substrateconjugated nanoparticles (Azith-and Clarith-AuNRs), while the lower affi nity TriKeto conjugate was unaffected. DFSM effl ux experiments further indicated a signifi cant role for P-gp in the retention of the nanoscale conjugates, where competitive binding (inhibition) decreased both the total amount and rate of nanoparticle effl ux. Again, the lack of P-gp competitive accumulation for TriKeto-AuNRs in Figure 2 b relative to free TriKeto ligand in Figure S3 suggests a signifi cant role for P-gp in the endosomal traffi cking of multivalent nanoparticles. Together, accumulation and effl ux data support a role ligand-dependent intracellular traffi cking of nanoparticles bearing P-gp substrates. Although the effects observed here may be fully attributable to P-gp alone, inhibitors such as the verapamil [ 27 ] and cyclosporine [ 28 ] have also been shown to enhance autophagic vesicle formation that could either augment lysosomal trapping or impair endosomal recycling, partially contributing to the observed changes in cellular traffi cking. The fact that changes in accumulation occurred in both a ligand-and cell phenotype-selective manner however, do support a significant role for the protein in the uptake and retention of nanoparticle-drug conjugates. While studies to determine the precise mechanism by which P-gp may facilitate direct/indirect cellular traffi cking of nanoscale drug carriers are currently underway, subcellular localization, liganddependent accumulation, and effl ux data provide important insights into these contributions and their relevance to nanoscale drug delivery.
In summary, we have demonstrated ligand-dependent accumulation and effl ux of nanoscale drug carriers bearing substrate ligands for MDR1 P-glycoprotein (P-gp). Using PEGylated gold nanorod-drug conjugates, we found that the cellular accumulation of nanoparticles conjugated with substrates for P-gp was signifi cantly enhanced following competitive inhibition of P-gp, while low-affi nity P-gp substrate-conjugated nanoparticles were unaffected. Live-cell imaging experiments indicated that both the amount and rate of nanoparticle effl ux could be signifi cantly decreased small 2014, 10, No. 9, 1719-1723 communications following the administration of small molecule inhibitors of P-gp. Although, the recognition and traffi cking of numerous small molecule chemotherapeutics, antibiotics, and imaging agents by P-gp is well-described, interactions of the protein with nanoscale drug carriers is poorly understood. These fi ndings suggest that nanoscale drug carriers incorporating P-gp substrates may benefi t through minimization of surface presentation or the incorporation of P-gp inhibiting small molecules or siRNA. [ 29 ] Rapid screening methods for P-gp-dependent cellular accumulation of newly developed nanoscale drug carriers may also contribute to improved chemotherapeutic interventions.
Supporting Information
Detailed synthetic/experimental methods and supporting data. Supporting Information is available on the WWW under http:// www.small-journal.com or from the author. Figure 3 . Real-time effl ux kinetics of P-gp substrate-conjugated nanoparticles. J774.2 cells were loaded with 0.01 nM azithromycingold nanorods for 24 h, after which nanoparticle-containing media was removed and replaced by fresh media spiked with the P-gp-competitive inhibitor verapamil. a ) Live-cell dark-fi eld scattering microscopy and ( b ) quantitative image analysis of nanoparticle cell effl ux kinetics in the presence and absence of verapamil. I SCA represents the relative background-subtracted scattering intensity of the nanoparticles. Error in (b) is plotted as SEM of mean pixel intensity per fi eld of view and rate constants represent mean ± SD of a one-phase exponential fi t. Scale bar, 100 µm.
